CJC-1295 is a long-acting synthetic analogue of Growth Hormone Releasing Hormone (GHRH). It stimulates the pituitary gland to release growth hormone (GH) in a more natural, pulsatile manner, which in turn increases levels of Insulin-like Growth Factor 1 (IGF-1). For healthspan, the goal is to restore youthful GH/IGF-1 levels to support tissue repair, body composition, and sleep quality, though the long-term effects on aging are still debated.
Verdict
Potent GH booster with unproven longevity benefits and significant safety concerns.
HEALTHSPAN IMPACT
Moderate
RISK LEVEL
High
EVIDENCE GRADE
B
MONTHLY COST
$160 - $320
Protocol
- 1000-2000 mcg administered subcutaneously once or twice per week due to its long half-life.
Flags
- Requires subcutaneous injection and sterile technique.
- Long-term elevation of IGF-1 is controversially linked to increased cancer risk.
- Often sourced from unregulated 'research chemical' suppliers, posing quality and purity risks.
- Should not be used by individuals with active or suspected cancer.
- Potential side effects include water retention, joint pain, and nerve compression.
- Interacts with corticosteroids, which can blunt the GH-releasing effect.